Logo image
TGF-β receptors-I and -II immunoexpression in Alzheimer’s disease: a comparison with aging and progressive supranuclear palsy
Journal article   Peer reviewed

TGF-β receptors-I and -II immunoexpression in Alzheimer’s disease: a comparison with aging and progressive supranuclear palsy

C.F Lippa, K.C Flanders, E.S Kim and S Croul
Neurobiology of aging, v 19(6), pp 527-533
1998
PMID: 10192211

Abstract

Alzheimer’s disease Cytokine Dementia Glia Receptor TGF-β
The transforming growth factor -βs (TGF-βs) influence cell survival, and TGF-β2 shows increased immunoexpression in neurofibrillary tangle-bearing neurons and reactive glia in Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). We compared immunohistochemical expression of TGF-β type I (RI) and type II (RII) receptors in eight patients with AD, eight controls and three cases of progressive supranuclear palsy. Mild intraneuronal immunoreactivity for the RI receptor was observed in all cases. Intraneuronal TGF-β RII receptor immunoexpression was more common in all groups, and its frequency did not differ between groups. We observed increased immunoreactivity for both RI and RII subtypes in reactive glia in the AD frontal cortex (RI: U = 0.5, p = 0.002; and RII: U = 9.000, p = 0.006) and parahippocampal gyrus (RI: U = 9.500, p = 0.013; RII: U = 14.5, p = 0.05) compared to control cases. We conclude that TGF-β RI and II immunoreactivity is increased in reactive glia in AD and progressive supranuclear palsy, and RI immunoreactivity may occasionally be increased in neurons in cases with advanced AD.

Metrics

9 Record Views
30 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Geriatrics & Gerontology
Neurosciences
Logo image